Skip to main content
  • Forums
  • Log in
  • Contact us
  • Policy
www.notifylibrary.org
  • The Notify Project
    • History
    • Who we are
    • Interviews
        1. Health authorities
        2. The Experts
    • Useful links
    • Global consultation reports
  • Search Library
    • Search tutorial
    • Adverse occurrence search
    • Reference search
    • Bibliographic list
        1. Authors
        2. Keywords
    • Add or update record
    • Editorial Group Tools
        1. MPHO taxonomy
        2. Adv. occurrence taxonomy
        3. Imputability table
        4. VIDEO TUTORIAL
    • Database content analysis
  • Notify Booklet
    • 1 INTRODUCTION
    • 2 THE V&S CHAIN FOR MPHOs
    • 3 VIGILANCE AND SURVEILLANCE: HISTORY AND BASIC ELEMENTS
    • 4 MEDICAL PRODUCTS OF HUMAN ORIGIN (MPHO) - DONATION AND ETHICS
    • ANNEX 1. Notify Library - MPHO type taxonomy
    • 5 TOWARDS A GLOBAL GOVERNANCE OF MPHO
    • 6 THE V&S SYSTEM IS PRIMARILY A RESPONSIBILITY FOR HEALTH AUTHORITIES
    • 7 ORGANIZATION FOR A COMPREHENSIVE - VIGILANCE & SURVEILLANCE SYSTEM
    • 8 VIGILANCE & SURVEILLANCE - RECOGNITION RELIES ON HEALTH CARE STAFF
    • 9 INVESTIGATING OCCURRENCES THAT COULD CAUSE HARM - LEARNING FROM ERRORS
    • 10 PROJECT NOTIFY
    • 11 THE NOTIFY DATABASE - LEARNING FROM VIGILANCE
    • 12 RISKS ASSOCIATED WITH LIVING DONATION
    • 13 HARM TO RECIPIENT - INFECTIONS
    • 14 HARM TO RECIPIENT - NON INFECTIOUS BLOOD TRANSFUSION REACTIONS
    • 15 HARM TO RECIPIENTS - MALIGNANCY
    • 16 HARM TO RECIPIENTS - GENETIC TRANSMISSIONS - HPC
    • 17 HARM TO RECIPIENTS - GENETIC TRANSMISSIONS - gamets and embryos
    • 18 CHARACTERISTICS, HANDLING AND CLINICAL ERRORS
    • 19 TRACEABILITY, AN ABSOLUTE PRE-REQUISITE FOR MPHO SAFETY
    • ANNEX 2. Notify Library - Adverse occurrence type taxonomy
    • REFERENCES
  • Background Documents
Home / The Notify Booklet / 14 Investigating Harm to Recipients - Malignancy / 14.3 Providing guidance on intermediate steps to take for index recipient and other potentially affected recipients
  • Download Booklet.pdf  NEW 

 

  • 1 Introduction
  • 2 The V&S Chain for MPHOs
  • 3 History of Vigilance and Surveillance
  • 4 Medical products of Human Origin (MPHO)
  • 5 Towards a global governance of MPHO
  • 6 The V&S system is primarily a responsibility for health authorities
  • 7 Organization for a comprehensive Vigilance & Surveillance System
  • 8 Vigilance & Surveillance — Recognition relies on health care staff
  • 9 Investigating occurrences that could cause harm – Learning from Errors
  • 10 Project NOTIFY
  • 11 The NOTIFY Database - Learning from Vigilance
  • 12 Risks Associated with Living Donation
  • 13 Investigating Harm to Recipients - Infections
  • 14 Investigating Harm to Recipients - Malignancy
    • 14.1 Donor malignancies known to be transmitted or known not to be transmittedby cancer, organ and cell type
    • 14.2 Providing guidance on early detection and prevention of transmission
    • 14.3 Providing guidance on intermediate steps to take for index recipient and other potentially affected recipients
      • 14.3.1 Tracing, alerting and notification
      • 14.3.2 Graft removal and cessation of immunosuppression
      • 14.3.3 Immunotherapy
      • 14.3.4 Conventional treatment strategies based upon cancer type if organ, tissue or cell cannot be removed
    • 14.4 Providing guidance on steps to investigate and confirm the imputability of malignancy transmission
  • 15 Investigating Harm to Recipients — Genetic Transmissions – HPSC
  • 16 Investigating Harm to Offspring - Genetic Transmissions - Gametes and Embryos
  • 17 Characteristics, handling and clinical errors
  • 18 Traceability, an absolute pre-requisite for MPHO safety
  • 19 References

14.3 Providing guidance on intermediate steps to take for index recipient and other potentially affected recipients

  • 14.3.1 Tracing, alerting and notification
  • 14.3.2 Graft removal and cessation of immunosuppression
  • 14.3.3 Immunotherapy
  • 14.3.4 Conventional treatment strategies based upon cancer type if organ, tissue or cell cannot be removed
‹ 14.2.2 Living Donors up 14.3.1 Tracing, alerting and notification ›
↑
  • Forums
  • Log in
  • Contact us
  • Policy

Disclaimer

The cases, bibliography and associated comments included in this website and database have been provided by experts worldwide and reviewed by voluntary editorial working groups. The data and information is not guaranteed to be complete or to be fully up to date at any particular moment and it reflects the knowledge and views of the experts participating, not those of the World Health Organisation or the Italian National Transplant Centre.